Close Menu

More articles about Reproductive Health

The acquisition will bring to Invitae single-molecule, cell-free DNA analysis technology and enable lower cost NIPS testing.

Scientists from the UK and China discussed two new NIPTs that include single-gene disorders and a study to estimate disease recurrence risk in families.

The study showed that the Zeesan test kit and qPCR instrument could be used for near-patient HPV typing of 94 samples in 2.5 hours.

The Aptima BV test detects bacterial vaginosis and the Aptima CV/TV detects and differentiates candida infections from trichomonas.

The self-administered test is designed to detect human chorionic gonadotropin levels in women as early as six days before a first missed period.

The company received support from a Johns Hopkins University center focused on point-of-care device development for sexually transmitted infections.

The Hologic Aptima Combo 2 and the Cepheid Xpert CT/NG assays have now been cleared for use in throat and rectum samples.

The guidelines, drafted with support from PerkinElmer, calls for universal screening of pregnant women for preterm preeclampsia during the first trimester.

The firm has developed a digital platform that determines whether patients meet guidelines for genetic testing, and if so, what test they should receive.

The company's first quarter revenues were driven by sales of its noninvasive prenatal screening and carrier screening tests.

The direct-to-consumer at-home health testing firm intends to use the funds to expands its platform development and supply logistics in North America.

Elucigene has been developing in vitro diagnostics for oncology and reproductive health, including tests for cystic fibrosis screening and prenatal fetal aneuploidy screening.

The new assay is part of the company's prenatal and women's health offerings, but it is also developing a preeclampsia test and technology for gastrointestinal testing.

To help fund the acquisition, Yourgene Health is planning to sell at least £10.0 million in newly issued shares to institutional investors.

The Austin, Texas-based company offers more than 30 tests, including those for food sensitivity, fertility and women's hormones, sexually transmitted diseases, and thyroid.

The companies will combine their respective technologies to develop mass spectrometry-based proteomics assays for adverse pregnancy outcomes.

Yikon's test uses next-generation sequencing to screen embryos for chromosomal aneuploidy prior to implantation and does not require a biopsy.

The company said its higher revenues were due in part to international performance including continued penetration of Middle Eastern and Asian markets.

A study of 10 commercial labs offering NIPT in the US found that none followed all recommendations for reporting results and informing patients and providers.

The company will use the money to launch its first product, Unity, a noninvasive prenatal test for recessively inherited single-gene disorders.

Pages